SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Huai Heng Loh, Anne Yee, Huai Seng Loh, Norlela Sukor, Nor Azmi Kamaruddin, Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis, Primary Care Diabetes, 2016, 10, 3, 210

    CrossRef

  2. 2
    Saud Al Sifri, Kashif Rizvi, Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence, Diabetes Therapy, 2016,

    CrossRef

  3. 3
    Awadhesh Kumar Singh, Ritu Singh, Is gliclazide a sulfonylurea with difference? A review in 2016, Expert Review of Clinical Pharmacology, 2016, 1

    CrossRef

  4. 4
    Mussa H. Almalki, Fahad Alshahrani, Options for Controlling Type 2 Diabetes during Ramadan, Frontiers in Endocrinology, 2016, 7,

    CrossRef

  5. 5
    Shaun Wen Huey Lee, Jun Yang Lee, Christina San San Tan, Chee Piau Wong, Strategies to Make Ramadan Fasting Safer in Type 2 Diabetics, Medicine, 2016, 95, 2, e2457

    CrossRef

  6. 6
    André J Scheen, A review of gliptins for 2014, Expert Opinion on Pharmacotherapy, 2015, 16, 1, 43

    CrossRef

  7. 7
    Jean Claude Mbanya, Saud Al-Sifri, Aly Abdel-Rahim, Ilhan Satman, Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach, Diabetes Research and Clinical Practice, 2015, 109, 2, 226

    CrossRef

  8. 8
    M. Ibrahim, M. Abu Al Magd, F. A. Annabi, S. Assaad-Khalil, E. M. Ba-Essa, I. Fahdil, S. Karadeniz, T. Meriden, A. A. Misha'l, P. Pozzilli, S. Shera, A. Thomas, S. Bahijri, J. Tuomilehto, T. Yilmaz, G. E. Umpierrez, Recommendations for management of diabetes during Ramadan: update 2015, BMJ Open Diabetes Research & Care, 2015, 3, 1, e000108

    CrossRef

  9. 9
    L. J. Gray, J. Dales, E. M. Brady, K. Khunti, W. Hanif, M. J. Davies, Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis, Diabetes, Obesity and Metabolism, 2015, 17, 7
  10. 10
    Alisa K. Escaño, A worldwide yearly survey of new data in adverse drug reactions, 2015,

    CrossRef

  11. 11
    E. M. Brady, M. J. Davies, L. J. Gray, M. A. Saeed, D. Smith, W. Hanif, K. Khunti, A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial, Diabetes, Obesity and Metabolism, 2014, 16, 6
  12. 12
    Sarah Louise Pampel, Gliptin ist für viele die richtige Antwort, Info Diabetologie, 2014, 8, 3, 61

    CrossRef

  13. 13
    S. Halimi, M. Lévy, Prise en charge des patients diabétiques de type 2 durant le Ramadan : quelle place pour les inhibiteurs de la DPP-4 ?, Médecine des Maladies Métaboliques, 2014, 8, 3, 299

    CrossRef

  14. 14
    Gillian M. Keating, Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus, Drugs, 2014, 74, 5, 587

    CrossRef

  15. 15
    I. Ahmed, Ramadan: type 2 diabetes and risk of hypoglycaemia, International Journal of Clinical Practice, 2013, 67, 10